产品
编 号：F747899
分子式：C31H25FN4O6S
分子量：600.62
分子式：C31H25FN4O6S
分子量：600.62
产品类型
规格
价格
是否有货
结构图
CAS No: 1926985-18-3
产品详情
生物活性：
Anticancer agent 53 is a potent anticancer agent. Anticancer agent 53 shows in vitro cytotoxicity. Anticancer agent 53 induces apoptosis and cell cycle arrest in S/G2/M phases. Anticancer agent 53 shows antitumor activity with no apparent toxicity.
体内研究：
Anticancer agent 53 (5, 25 and 50 mg/kg; IP) shows no apparent toxicity to mouse liver, kidney and hemopoietic system.Anticancer agent 53 (2 mg/kg; i.v; every other day for two weeks) shows antitumor effect in HCC mouse model.Animal Model:Balb/C mice
Dosage:5, 25 and 50 mg/kg (saline with 5% DMSO and 5% Cremophor EL)
Administration:I.p.
Result:Showed no body weight loss, no significant liver damage, no significant damage occurred in spleens and livers.
Animal Model:6-8 weeks Female BALB/c nude mice (Hep3B cells)
Dosage:1, 2 mg/kg
Administration:I.v., every other day for total 7 doses
Result:Significantly inhibited tumor growth with an average body weight of 24 g and an average tumor volume of 3800 mm at 1 mg/kg and an average body weight of 22 g and average tumor volume 2380 mm at 2 mg/kg.
Animal Model:6-8 weeks FVB/N mice (HCC mouse model)
Dosage:2 mg/kg
Administration:I.v.; every other day for two weeks
Result:Inhibited the tumor growth and reduced the liver weights, and t inhibited proliferation of HCC tissues.
体外研究：
Anticancer agent 53 (compound c20) (0-1000 nM; 72 h) shows cytotoxicity with IC50s of 2.3, 42.0, 4.3, 96.3, 24.0, 47.4 nM for Hep3B, MCF7, A549, MDA-MB-231, KB, KB-vin cells, respectively.Anticancer agent 53 (0.025, 0.05, 0.1 μM; 48 h) induces apoptosis and cell cycle arrest in S/G2/M phases.Anticancer agent 53 (0.1. 0.2 μM; 6 h) inhibits topoisomerase I activity in A549 cells.
Anticancer agent 53 is a potent anticancer agent. Anticancer agent 53 shows in vitro cytotoxicity. Anticancer agent 53 induces apoptosis and cell cycle arrest in S/G2/M phases. Anticancer agent 53 shows antitumor activity with no apparent toxicity.
体内研究：
Anticancer agent 53 (5, 25 and 50 mg/kg; IP) shows no apparent toxicity to mouse liver, kidney and hemopoietic system.Anticancer agent 53 (2 mg/kg; i.v; every other day for two weeks) shows antitumor effect in HCC mouse model.Animal Model:Balb/C mice
Dosage:5, 25 and 50 mg/kg (saline with 5% DMSO and 5% Cremophor EL)
Administration:I.p.
Result:Showed no body weight loss, no significant liver damage, no significant damage occurred in spleens and livers.
Animal Model:6-8 weeks Female BALB/c nude mice (Hep3B cells)
Dosage:1, 2 mg/kg
Administration:I.v., every other day for total 7 doses
Result:Significantly inhibited tumor growth with an average body weight of 24 g and an average tumor volume of 3800 mm at 1 mg/kg and an average body weight of 22 g and average tumor volume 2380 mm at 2 mg/kg.
Animal Model:6-8 weeks FVB/N mice (HCC mouse model)
Dosage:2 mg/kg
Administration:I.v.; every other day for two weeks
Result:Inhibited the tumor growth and reduced the liver weights, and t inhibited proliferation of HCC tissues.
体外研究：
Anticancer agent 53 (compound c20) (0-1000 nM; 72 h) shows cytotoxicity with IC50s of 2.3, 42.0, 4.3, 96.3, 24.0, 47.4 nM for Hep3B, MCF7, A549, MDA-MB-231, KB, KB-vin cells, respectively.Anticancer agent 53 (0.025, 0.05, 0.1 μM; 48 h) induces apoptosis and cell cycle arrest in S/G2/M phases.Anticancer agent 53 (0.1. 0.2 μM; 6 h) inhibits topoisomerase I activity in A549 cells.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备